Danish biotech Breye Therapeutics has raised €67.5 million to advance an oral eye disease drug candidate into a Phase 2 ...

Aptadir Therapeutics has raised €40 million in seed funding to advance an RNA therapy designed to reactivate the gene ...

Newron Pharmaceuticals will expand its Phase 3 evenamide trial outside the U.S. after the FDA decided to maintain a hold on ...

Sweden’s Nanexa has granted Novo Nordisk a global license to use its PharmaShell drug delivery technology in up to five ...

Swiss biotech Addex Therapeutics has regained global rights to a GABA-B drug portfolio from Indivior, including a candidate ...

The 2025 AseBio Report shows a Spanish biotech ecosystem that is not only expanding, but attracting capital at a new scale: ...

Roche’s sefaxersen significantly reduced proteinuria in a Phase 3 IgA nephropathy (IgAN) trial, but the Swiss pharma stopped ...

PBIOVIAN has appointed Ponchi Kantt-Neaz as Global Executive Business Director, marking an important milestone in the company’s global commercial strategy and further strengthening its commercial ...

Novartis is paying $125 million (€106 million) to acquire global rights to Sironax’s brain delivery platform, exercising an ...

Scarlet Therapeutics has raised £3.2 million (€3.7 million) to take therapies based on red blood cells (RBCs) to in vivo proof of concept, building on evidence that natural and lab-grown cells have ...

Novartis has stopped developing its TREM2 antibody VHB937 (lifonebart) in amyotrophic lateral sclerosis (ALS) after the ...

For BioNTech, 2026 could become one of the most decisive years since its pandemic-driven breakthrough. The pipeline is broad, the coffers are well stocked, partnerships are numerous, and the outlook ...